The present application relates to a process for the preparation of lactones by enzymatic oxidation of lactols. The lactones, produced thus may be useful for the synthesis of statins, including but not limited to, cerivastatin, pitavastatin, fluvastatin, pravastatin, atorvastatin, rosuvastatin etc. The present application also relates to a crystalline form of (4R,6S)-6-(chloromethyl)tetrahydro-2H-pyran-2,4-diol (2a).

The invention provides a method of purification of an anti-VEGF antibody using chromatographic technique. The method involves the use of cation-exchange chromatography for the purification of the antibody wherein the cation exchange eluate is collected as a whole without the need for fractionation. The purified antibody can be used as a therapeutic composition.

The present application relates to a series of substituted pyra- zolopyridin-6-amines having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. Wherein R, R1, R2, Ra, Raa, Rb and n are as defined herein. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I). The compounds of this application are useful as CETP inhibitors for increasing HDL cholesterol and decreasing LDL cholesterol in a patient.

The present application relates to cycloalkylpyridin-2-amines derivates of formula (I) or stereoisomers thereof or pharmaceutically acceptable salts thereof. The present application also relates to the process for the preparation of compounds of formula (I). The present application further describes the compounds of formulat (I) as cholesteryl ester-transfer protein (CETP) inhibitors. The present application further relates to pharmaceutical compositions comprising compounds of formula (I) or stereoisomers thereof or pharmaceutically acceptable salts thereof.

Provided is a method for purification of TNFR:Fc fusion protein comprising hydrophobic interaction chromatography, wherein the buffer solution used in the said chromatography does not contain any additives.

Disclosed is the process for the preparation of 4-(fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5-formyl-pyrimidine of formula (I), which is the intermediate of rosuvastatin calcium. Purification of substantially pure acetonide protected tert-butyl ester of rosuvastatin (II) and its use for the preparation of substantially pure amorphous rosuvastatin calcium are also disclosed.

The invention provides a method of purification of antibodies using chromatographic technique. The method involves the use of anion-exchange chromatography for the purification of the antibody. The purified antibody can be used as a therapeutic composition.

The invention provides a method of purification of antibodies using chromatographic technique. The method involves the use of cation -exchange chromatography for the purification of the antibody. The purified antibody can be used as a therapeutic composition.

Aspects of the present invention relate to amorphous form of mirabegron, amorphous solid dispersion of mirabegron, process for its preparation, processes for preparation of a form crystal and β form crystal of mirabegron and pharmaceutical composition thereof.

The present application provide processes for the preparation of fingolimod and its pharmaceutically acceptable salts, process for the purification of fingolimod hydrochloride and process for the preparation of amorphous fingolimod hydrochloride.